New adaptive therapy aims to outsmart prostate cancer
NCT ID NCT03511196
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 31 times
Summary
This early-phase trial tests an adaptive approach to hormone therapy for men with stage IV prostate cancer that still responds to hormone treatment. Instead of a fixed schedule, the treatment is adjusted based on PSA levels. The study includes 17 participants and combines standard drugs (abiraterone and prednisone) with a GnRH agonist. The main goal is to see if men can stay on the study for at least a year without their cancer worsening.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Androgen deprivation therapy (ADT) with leuprolide, goserelin, or triptorelin, plus abiraterone and prednisone
What this could lead to
If successful, this could point toward a personalized treatment schedule that delays cancer progression while reducing side effects for men with advanced prostate cancer.
What could go wrong
This is a very early phase 1b trial with only 17 participants, so results may not apply to all patients. The adaptive approach may not improve outcomes or could lead to faster progression in some cases.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.